Amendment to the Cross-License Agreement By and Between MedImmune, LLC and Xencor, Inc.Xencor Inc • February 24th, 2021 • Pharmaceutical preparations
This amendment ("Amendment") to the license agreement effected December 19, 2012 (the "Agreement") by and between MedImmune, LLC, a limited liability company organized under the laws of Delaware, having a principal place of business at One MedImmune Way, Gaithersburg MD 20878 (“MedImmune”) and Xencor, Inc., a Delaware corporation with an office at 111 W. Lemon Ave., Monrovia, CA 91016 ("Xencor"), is effective as of January 2, 2020. Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Agreement.
AMENDMENT No. 1 to the Research and License Agreement between Xencor, Inc. and Amgen Inc.Xencor Inc • February 24th, 2021 • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) is entered into as of November 22, 2019 (“Amendment No. 1 Effective Date”) by and between Xencor, Inc., a corporation organized under the laws of the State of Delaware (“Xencor”), having an address of 111 West Lemon Avenue, Monrovia, California 91016 and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320- 1799, USA (“Amgen”). Xencor and Amgen are each referred to individually as a “Party” and together as the “Parties”.
FIFTH AMENDMENT TO LEASELease • February 24th, 2021 • Xencor Inc • Pharmaceutical preparations
This FIFTH AMENDMENT TO LEASE (this “Amendment”) is made and effective as of October 31, 2020 (the “Effective Date”) by and between 111 LEMON INVESTORS LLC, a California limited liability company successor-in-interest to BF Monrovia, LLC, a California limited liability company (“Landlord”) and XENCOR, INC., a Delaware corporation successor-in-interest to Xencor, Inc., a California corporation (“Tenant”).
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEENCollaboration and License Agreement • February 24th, 2021 • Xencor Inc • Pharmaceutical preparations • New York
This Collaboration and License Agreement (the “Agreement”) is made and effective as of December 4, 2020 (the “Execution Date”) by and between Xencor, Inc., a Delaware corporation (“Xencor”), on the one hand, and Janssen Biotech, Inc., a Pennsylvania company (“Janssen”), on the other hand. Xencor and Janssen are referred to herein each individually as a “Party” and collectively as the “Parties.”
First Amendment to the License Agreement By and Between Xencor, Inc. and MorphoSys AGCollaboration and License Agreement • February 24th, 2021 • Xencor Inc • Pharmaceutical preparations • New York
This first amendment ("Amendment") to the Collaboration and License Agreement dated June 27, 2010 (the “Agreement”) by and between Xencor, Inc., a Delaware corporation with its principal offices at 111 West Lemon Avenue, Monrovia, CA 91016 (“Xencor”), and MorphoSys AG, a German corporation with its principal offices at Semmelweisstrasse 7, 82152 Planegg, Germany (“MorphoSys”) is effective as of the date of last signature to this Amendment. Capitalized terms not otherwise defined herein shall have the meanings ascribed in the Agreement.
THIRD AMENDMENT TO THE LICENSE AGREEMENT BY AND BETWEENLicense Agreement • February 24th, 2021 • Xencor Inc • Pharmaceutical preparations • New York
This third amendment ("Amendment") to the COLLABORATION AND LICENSE AGREEMENT dated June 27, 2010, as amended on March 23, 2012, and on January 8, 2020 (such second amendment being wrongly named “first amendment” thereunder shall be regarded and referred to as the second amendment) (collectively, the “Agreement”), by and between XENCOR, INC., a Delaware corporation with its principal offices at 111 West Lemon Avenue, Monrovia, CA 91016, USA (“Xencor”), and MORPHOSYS AG, a German corporation with its principal offices at Semmelweisstrasse 7, 82152 Planegg, Germany (“MorphoSys”) is effective as of the date of last signature to this Amendment. Capitalized terms not otherwise defined herein shall have the meanings ascribed in the Agreement.
